These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
593 related articles for article (PubMed ID: 30644073)
1. Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond. Krichevsky AM; Uhlmann EJ Neurotherapeutics; 2019 Apr; 16(2):319-347. PubMed ID: 30644073 [TBL] [Abstract][Full Text] [Related]
2. Drug-induced modifications and modulations of microRNAs and long non-coding RNAs for future therapy against Glioblastoma Multiforme. Janaki Ramaiah M; Divyapriya K; Kartik Kumar S; Rajesh YBRD Gene; 2020 Jan; 723():144126. PubMed ID: 31589963 [TBL] [Abstract][Full Text] [Related]
3. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression. Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962 [TBL] [Abstract][Full Text] [Related]
5. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797 [TBL] [Abstract][Full Text] [Related]
6. Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier. Sharma RK; Calderon C; Vivas-Mejia PE Front Med Technol; 2021; 3():678593. PubMed ID: 35047931 [TBL] [Abstract][Full Text] [Related]
7. RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme. Singh P; Singh A; Shah S; Vataliya J; Mittal A; Chitkara D Mol Pharm; 2020 Nov; 17(11):4040-4066. PubMed ID: 32902291 [TBL] [Abstract][Full Text] [Related]
8. Construction of lncRNA-associated ceRNA networks to identify prognostic lncRNA biomarkers for glioblastoma. Liu Z; Wang X; Yang G; Zhong C; Zhang R; Ye J; Zhong Y; Hu J; Ozal B; Zhao S J Cell Biochem; 2020 Jul; 121(7):3502-3515. PubMed ID: 32277520 [TBL] [Abstract][Full Text] [Related]
9. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies. Taniguchi H; Suzuki Y; Imai K; Adachi Y Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833 [TBL] [Abstract][Full Text] [Related]
10. Identification and functional characterization of lncRNAs acting as ceRNA involved in the malignant progression of glioblastoma multiforme. Zhang K; Li Q; Kang X; Wang Y; Wang S Oncol Rep; 2016 Nov; 36(5):2911-2925. PubMed ID: 27600337 [TBL] [Abstract][Full Text] [Related]
11. Exosomal noncoding RNAs: key players in glioblastoma drug resistance. Movahedpour A; Khatami SH; Khorsand M; Salehi M; Savardashtaki A; Mirmajidi SH; Negahdari B; Khanjani N; Naeli P; Vakili O; Taheri-Anganeh M Mol Cell Biochem; 2021 Nov; 476(11):4081-4092. PubMed ID: 34273059 [TBL] [Abstract][Full Text] [Related]
12. Molecular, histopathological, and genomic variants of glioblastoma. Karsy M; Huang T; Kleinman G; Karpel-Massler G Front Biosci (Landmark Ed); 2014 Jun; 19(7):1065-87. PubMed ID: 24896337 [TBL] [Abstract][Full Text] [Related]
13. Current progress for the use of miRNAs in glioblastoma treatment. Tivnan A; McDonald KL Mol Neurobiol; 2013 Dec; 48(3):757-68. PubMed ID: 23625340 [TBL] [Abstract][Full Text] [Related]
14. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma. Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727 [TBL] [Abstract][Full Text] [Related]
15. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b. El Fatimy R; Subramanian S; Uhlmann EJ; Krichevsky AM Mol Ther; 2017 Feb; 25(2):368-378. PubMed ID: 28153089 [TBL] [Abstract][Full Text] [Related]
17. Non-coding RNAs enhance the apoptosis efficacy of therapeutic agents used for the treatment of glioblastoma multiform. Ghaemi S; Fekrirad Z; Zamani N; Rahmani R; Arefian E J Drug Target; 2022 Jul; 30(6):589-602. PubMed ID: 35282758 [TBL] [Abstract][Full Text] [Related]